NasdaqGS:CUTR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Cutera, Inc., a medical device company, engages in the research, development, manufacture, marketing, and servicing of laser and energy-based aesthetics systems for practitioners worldwide.


Snowflake Analysis

Adequate balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Cutera's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CUTR has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

4.7%

CUTR

0.2%

US Medical Equipment

2.5%

US Market


1 Year Return

-55.7%

CUTR

15.5%

US Medical Equipment

16.3%

US Market

Return vs Industry: CUTR underperformed the US Medical Equipment industry which returned 15.4% over the past year.

Return vs Market: CUTR underperformed the US Market which returned 16.3% over the past year.


Shareholder returns

CUTRIndustryMarket
7 Day4.7%0.2%2.5%
30 Day29.0%8.8%5.3%
90 Day17.7%10.4%16.3%
1 Year-55.7%-55.7%16.4%15.5%18.8%16.3%
3 Year-56.3%-56.3%77.1%72.3%45.0%35.7%
5 Year-1.1%-1.1%120.4%103.3%75.8%56.8%

Price Volatility Vs. Market

How volatile is Cutera's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cutera undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CUTR ($14.9) is trading below our estimate of fair value ($37.93)

Significantly Below Fair Value: CUTR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CUTR is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: CUTR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CUTR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CUTR is overvalued based on its PB Ratio (4.8x) compared to the US Medical Equipment industry average (4x).


Next Steps

Future Growth

How is Cutera forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

55.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CUTR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CUTR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CUTR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CUTR's revenue (28% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: CUTR's revenue (28% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CUTR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cutera performed over the past 5 years?

-30.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CUTR is currently unprofitable.

Growing Profit Margin: CUTR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CUTR is unprofitable, and losses have increased over the past 5 years at a rate of 30.4% per year.

Accelerating Growth: Unable to compare CUTR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CUTR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.7%).


Return on Equity

High ROE: CUTR has a negative Return on Equity (-54.33%), as it is currently unprofitable.


Next Steps

Financial Health

How is Cutera's financial position?


Financial Position Analysis

Short Term Liabilities: CUTR's short term assets ($96.9M) exceed its short term liabilities ($44.6M).

Long Term Liabilities: CUTR's short term assets ($96.9M) exceed its long term liabilities ($16.3M).


Debt to Equity History and Analysis

Debt Level: CUTR's debt to equity ratio (13.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if CUTR's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CUTR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CUTR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Cutera current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CUTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CUTR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CUTR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CUTR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CUTR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Dave Mowry (58 yo)

1.08yrs

Tenure

US$3,493,095

Compensation

Mr. David H. Mowry, also known as Dave, is the Chief Executive Officer and Director at Cutera, Inc. since July 8, 2019. Mr. Mowry served as the Director, President and Chief Executive Officer of Vyaire Med ...


CEO Compensation Analysis

Compensation vs Market: Dave's total compensation ($USD3.49M) is above average for companies of similar size in the US market ($USD1.30M).

Compensation vs Earnings: Insufficient data to compare Dave's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
David Mowry
CEO & Director1.08yrsUS$3.49m0.22%
$ 566.2k
R. Richey
President1.58yrsUS$2.42mno data
Fuad Ahmad
Interim Chief Financial Officer0.75yrUS$160.65kno data
Michael Karavitis
Executive VP & Chief Technology Officer3yrsno datano data
Matthew Scalo
Vice President of Investor Relations & Corporate Developmentno datano datano data
Darren Alch
VP, General Counsel & Secretaryno datano datano data
Tanya Rodante
Director of Corporate Communicationsno datano datano data
Marina Kamenakis
Senior VP of Global Marketing & Clinical Development2.5yrsno datano data
Cindee Van Vleck
Head of Human Officer2.5yrsno datano data
Rajesh Madan
Vice President of Financeno datano datano data

2.0yrs

Average Tenure

54yo

Average Age

Experienced Management: CUTR's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David Mowry
CEO & Director1.08yrsUS$3.49m0.22%
$ 566.2k
Joseph Whitters
Independent Director1.5yrsUS$196.93k0.50%
$ 1.3m
Katherine Zanotti
Independent Director1.5yrsUS$191.93k0.057%
$ 148.2k
Gregory Barrett
Independent Director8.83yrsUS$208.49k0.38%
$ 992.7k
Timothy O'Shea
Independent Director16.33yrsUS$199.99k0.25%
$ 659.8k
J. Plants
Independent Chairman3.83yrsUS$201.74k0.091%
$ 236.5k

2.7yrs

Average Tenure

63yo

Average Age

Experienced Board: CUTR's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.4%.


Top Shareholders

Company Information

Cutera, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cutera, Inc.
  • Ticker: CUTR
  • Exchange: NasdaqGS
  • Founded: 1988
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$260.199m
  • Shares outstanding: 17.46m
  • Website: https://www.cutera.com

Number of Employees


Location

  • Cutera, Inc.
  • 3240 Bayshore Boulevard
  • Brisbane
  • California
  • 94005
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CUTRNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 2004
TJ9DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2004

Biography

Cutera, Inc., a medical device company, engages in the research, development, manufacture, marketing, and servicing of laser and energy-based aesthetics systems for practitioners worldwide. The company off ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/09 01:03
End of Day Share Price2020/08/07 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.